bryostatin-1


Also found in: Medical.

bryostatin-1

[¦brī·ə‚stat·ən ′wən]
(pharmacology)
A polyketide isolated from the bryozoan Bugula neritina that has both anticancer and immune modulating activity.
References in periodicals archive ?
PKC activation with Bryostatin-1 promotes BDNF expression and secretion, and synaptogenesis, and provides protective effects against a variety of neurotoxic factors such as amyloidosis, tauopathy, apoptosis, neuroinflammation, and oxidants.
Biopharmaceutical company Neurotrope Inc (NASDAQ:NTRP) disclosed on Monday the launch of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the research and clinical development of Bryostatin-1.
The study assessed safety and efficacy of Bryostatin-1 as a treatment of cognitive deficits in patients with moderate to severe AD.
Although the effects of anti-cancer compounds (4-HPR, 1[alpha],25[(OH).sub.2][D.sub.3], Bryostatin-1) have been examined in various leukemias, little information is available on the effects of these anti-cancer compounds in T-cell and B-cell derived ALL cell lines.
Bryostatin-1: pharmacology and therapeutic potential as a CNS drug.
Recently data from our lab proposed a synthesis of bryostatin-1 from a precursor tentatively identified in the sediment of the Bugula ecosystem (20).
Release date- 05082019 - NEW YORK - Neurotrope, Inc., a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today provided an update on clinical and corporate developments, including its ongoing confirmatory Phase 2 study of Bryostatin-1 in moderate to severe AD, and announced financial results for the second quarter ended June 30, 2019.
Neurotrope announced that it has initiated dosing in the final patient in the company's randomized, double-blind, placebo-controlled, confirmatory Phase 2 clinical trial of Bryostatin-1 in moderate to severe AD patients not on memantine.
M2 PHARMA-February 5, 2019-Neurotrope signs cooperative research and development agreement with the National Cancer Institute for Bryostatin-1 research and clinical development
It was reported yesterday that the contract has been signed for an accelerated synthesis of Alzheimer's drug, bryostatin-1. Prior to this synthetic route, the product had to be isolated from tons of natural sources to obtain grams of the drug.
Like tumor-promoting phorbol esters, the drug bryostatin-1, which does not promote tumors, is a potent activator of PKC (Smith et al., 1985; Kiss et al., 1991; Pettit, 1991), and is now being tested as an anti-cancer drug (Blackhall et al., 2001).
Neurotrope announced that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. Under the CRADA, Neurotrope will collaborate with the NCI's Center for Cancer Research, Pediatric Oncology Branch to develop a Phase I clinical trial testing the safety and toxicity of Bryostatin-1 in children and young adults with CD22 + leukemia and B-cell lymphoma.